The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Neoadjuvant nivolumab with or without IDO inhibitor in head and neck squamous cell carcinoma (HNSCC): Final pathologic and clinical outcomes.
 
Adam Luginbuhl
No Relationships to Disclose
 
Jennifer Maria Johnson
Consulting or Advisory Role - Bistol-Myers Squibb; Foundation Medicine; Rakuten Medical
Research Funding - AstraZeneca; Bristol-Myers Squibb; Merck
(OPTIONAL) Uncompensated Relationships - Taproot Health Inc
 
Elizabeth R Scott
No Relationships to Disclose
 
Larry Harshyne
No Relationships to Disclose
 
Elizaveta Flerova Flerova
No Relationships to Disclose
 
Madalina Tuluc
No Relationships to Disclose
 
Stacey Gargano
No Relationships to Disclose
 
Benjamin Leiby
No Relationships to Disclose
 
Matthew O. Old
No Relationships to Disclose
 
Nolan Seim
No Relationships to Disclose
 
Joseph M. Curry
Consulting or Advisory Role - Rakuten Medical
Research Funding - AstraZeneca
 
David M. Cognetti
Honoraria - Cortexyme; Rakuten Aspyrian
Consulting or Advisory Role - Rakuten Medical
 
Athanassios Argiris
Consulting or Advisory Role - Bristol-Myers Squibb; Merck Serono
Speakers' Bureau - AstraZeneca; Bristol-Myers Squibb; Debiopharm Group; Merck Serono
Research Funding - Bristol-Myers Squibb; Genentech/Roche
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Merck Serono